Simplex Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Simplex Trading’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$687K	Buy	35,300 +1,500	+4%	+$27.2K	﹤0.01%	3221
2026 Q1	$630K	Buy	33,800 +700	+2%	+$11.6K	﹤0.01%	3006
2025 Q4	$436K	Sell	33,100 -172,400	-84%	-$2.03M	﹤0.01%	3427
2025 Q3	$1.47M	Buy	205,500 +182,000	+774%	+$9.49M	﹤0.01%	2637
2025 Q2	$1.11M	Buy	+23,500	New	+$957K	﹤0.01%	2674
2024 Q3	–	Sell	-4,200	Closed	-$184K	–	9149
2024 Q2	$184K	Sell	4,200 -11,500	-73%	-$487K	﹤0.01%	4739
2024 Q1	$788K	Sell	15,700 -53,500	-77%	-$2.9M	﹤0.01%	3369
2023 Q4	$4.18M	Buy	69,200 +54,100	+358%	+$2.79M	﹤0.01%	1717
2023 Q3	$860K	Buy	+15,100	New	+$834K	﹤0.01%	2827

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Simplex Trading's MLTX Position: Q2 2026 in Review

Simplex Trading increased its MoonLake Immunotherapeutics (MLTX) stake by 439% in Q2 2026, buying an estimated $245K and bringing the position to 16,566 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #4139.

Simplex Trading first reported a position in MLTX in Q4 2023 and has held it in 6 quarters since. The position peaked at $2.12M in Q4 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Simplex Trading held 16,566 shares of MoonLake Immunotherapeutics worth $323K as of Q2 2026.
Simplex Trading bought 13,491 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $245K.
MoonLake Immunotherapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #4139 holding.
Simplex Trading first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 6 quarters since.
Simplex Trading's MoonLake Immunotherapeutics position peaked at $2.12M in Q4 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.